Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity

R.J. Jutten*, S.A.M. Sikkes, W.M. van der Flier, P. Scheltens, P.J. Visser, B.M. Tijms, Alzheimer's Disease Neuroimaging Initiative

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)

Abstract

Objective To investigate the influence of heterogeneity in disease progression for detecting treatment effects in Alzheimer disease (AD) trials, using a simulation study. Methods Individuals with an abnormal amyloid PET scan, diagnosis of mild cognitive impairment or dementia, baseline Mini-Mental State Examination (MMSE) score >= 24, global Clinical Dementia Rating (CDR) score of 0.5, and >= 1 follow-up cognitive assessment were selected from the Alzheimer's Disease Neuroimaging Initiative database (n = 302, age 73 +/- 6.7; 44% female; 16.1 +/- 2.7 years of education; 69% APOE epsilon 4 carrier). We simulated a clinical trial by randomly assigning individuals to a "placebo" and "treatment" group and subsequently computed group differences on the CDR-sum of boxes (CDR-SB), Alzheimer's Disease Assessment Scale-cognitive subscale-13 and MMSE after 18 months follow-up. We repeated this simulation 10,000 times to determine the 95% range of effect sizes. We further studied the influence of known AD risk factors (age, sex, education, APOE epsilon 4 status, CSF total tau levels) on the variability in effect sizes. Results Individual trajectories on all cognitive outcomes were highly variable, and the 95% ranges of possible effect sizes at 18 months were broad (e.g., ranging from 0.35 improvement to 0.35 decline on the CDR-SB). Results of recent anti-amyloid trials mostly fell within these 95% ranges of effect sizes. APOE epsilon 4 carriers and individuals with abnormal baseline tau levels showed faster decline at group level, but also greater within-group variability, as illustrated by broader 95% effect size ranges (e.g., +/- 0.70 points for the CDR-SB). Conclusions Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression. We provide guidance for a priori effect sizes on cognitive outcomes for detecting true change, which is crucial for future AD trials.
Original languageEnglish
Pages (from-to)E2673-E2684
Number of pages12
JournalNeurology
Volume96
Issue number22
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • MILD COGNITIVE IMPAIRMENT
  • CLINICAL-TRIALS
  • PREDICT TIME
  • DEMENTIA
  • SOLANEZUMAB
  • SCALE

Cite this